Seeking Alpha

Pluristem (PSTI -1.3%) says Cha Bio & Diostech (the company's South Korean PAD partner) has...

Pluristem (PSTI -1.3%) says Cha Bio & Diostech (the company's South Korean PAD partner) has filed an IND with Korean regulators for the use of PLX-PAD to treat intermittent claudication. The company says it is very pleased with "the pace at which [its] new partner is moving forward towards clinical trials." PSTI announced the partnership late last month. SA contributor Sharon di Stefano believes the partnership "positions PSTI to be a cell therapy leader."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs